Contrasting Orion OYJ (OTCMKTS:ORINY) & Catalyst Pharmaceuticals (NASDAQ:CPRX)

Orion OYJ (OTCMKTS:ORINY) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider and Institutional Ownership

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Orion OYJ has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Profitability

This table compares Orion OYJ and Catalyst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orion OYJ	27.14%	50.01%	29.82%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Earnings & Valuation

This table compares Orion OYJ and Catalyst Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orion OYJ	$2.14 billion	5.02	$566.04 million	$2.18	17.43
Catalyst Pharmaceuticals	$588.99 million	6.50	$214.33 million	$1.74	17.97

Orion OYJ has higher revenue and earnings than Catalyst Pharmaceuticals. Orion OYJ is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Orion OYJ and Catalyst Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orion OYJ	0	2	1	0	2.33
Catalyst Pharmaceuticals	0	5	1	2	2.63

Catalyst Pharmaceuticals has a consensus price target of $32.17, suggesting a potential upside of 2.90%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Orion OYJ.

Summary

Catalyst Pharmaceuticals beats Orion OYJ on 10 of the 14 factors compared between the two stocks.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.